U.S. markets closed

Sinovac Biotech Ltd. (SVA)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
6.470.00 (0.00%)
At close: 3:43PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.47
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's Range6.47 - 6.47
52 Week Range6.47 - 6.47
VolumeN/A
Avg. Volume0
Market Cap642.437M
Beta (5Y Monthly)0.05
PE Ratio (TTM)6.66
EPS (TTM)0.97
Earnings DateJun 28, 2021 - Jul 02, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
98% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Reuters

    UPDATE 1-Singapore sees early rush for Sinovac vaccine

    Offering Sinovac Biotech COVID-19 vaccines to the public in Singapore for the first time since Friday, several private clinics reported overwhelming demand for the Chinese-made shot, despite already available rival vaccines having far higher efficacy. Singapore has vaccinated almost half its 5.7 million population with at least one dose of the vaccines from Pfizer-BioNTech and Moderna. Both have shown efficacy rates of well over 90% against symptomatic disease in clinical trials, compared with Sinovac's 51%.

  • Reuters

    BioNTech shots have stronger antibody response than Sinovac, Hong Kong study shows - SCMP

    People who are vaccinated against COVID-19 with BioNTech's vaccine were found to have "substantially higher" levels of antibodies than those who received Sinovac's jab, the South China Morning Post reported https://bit.ly/3iX7S5t on Saturday, citing a Hong Kong study. Some who received the Sinovac vaccine might need a third booster shot as well, the newspaper said, citing lead researcher Professor Benjamin Cowling, an epidemiologist with the University of Hong Kong (HKU).

  • Reuters

    Singapore sees first day rush for Sinovac vaccine

    Offering Sinovac Biotech COVID-19 vaccines to the public in Singapore for the first time on Friday, several private clinics reported overwhelming demand for the Chinese-made shot, despite already available rival vaccines having far higher efficacy. Singapore has vaccinated almost half its 5.7 million population with at least one dose of the vaccines from Pfizer-BioNTech and Moderna. Both have shown efficacy rates of well over 90% against symptomatic disease in clinical trials, compared with Sinovac's 51%.